With the first healthy volunteer dosed in the Phase I trial, Psycheceutical prepares for a Phase II trial with PTSD patients to test NeuroDirect topical ketamine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,